Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Journal article

Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab.

Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core.

Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19–56% and 9–51% of patients, respectively.

Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.

Authors: Ponce Aix, S; Talbot, D; Ramaswamy, G; Cobo, M; Postmus, PE

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Future Medicine
• Journal: Future Oncology
• Volume: 16
• Issue: 12
• Pages: 749–762
• Publication date: 2020-03-31
• Acceptance date: 2020-03-06
• DOI: 10.2217/fon-2019-0796
• EISSN: 1744-8301
• ISSN: 1479-6694
• Language: English
• Keywords: quality of life; lung cancer symptom scale; nab-paclitaxel; EORTC QLQ-C30; FFR; durvalumab; EQ-5D-5L; non-small cell lung cancer